AZN — ASTRAZENECA PLC
—
NYSE ·
Health Care ·
Pharmaceuticals ·
CIK 901832 ·
United Kingdom
Last close
$166.58
Market Cap
$258.35B
52W High
$210.52
52W Low
$145.15
ADV30
3,151,930
Next earnings
2026-10-30
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 15,384,000,000 | 12,861,000,000 | 3,164,000,000 | 2,507,000,000 | 115,833,000,000 | 4,893,000,000 | 65,463,000,000 |
| Mar 2026 | 15,288,000,000 | 12,610,000,000 | 4,246,000,000 | 3,080,000,000 | 114,015,000,000 | 7,560,000,000 | 66,631,000,000 |
| Dec 2025 | 15,503,000,000 | 12,385,000,000 | 2,978,000,000 | 2,326,000,000 | 114,074,000,000 | 5,711,000,000 | 65,355,000,000 |
| Sep 2025 | 15,191,000,000 | 12,390,000,000 | 3,583,000,000 | 2,533,000,000 | 114,456,000,000 | 8,143,000,000 | 68,485,000,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$13,700,000,000
Investing CF
$-8,151,000,000
Financing CF
$-7,680,000,000
CapEx
$-7,656,000,000
Dividends Paid
$-4,902,000,000
Buybacks
—
EPS Diluted TTM
$6.64
As of
2026-08-09
Balance + Analyst (yfinance extras)
Retained Earnings
$12,592,000,000
Inventory
$6,932,000,000
Receivables
—
ST Investments
$75,000,000
EBIT TTM
$14,332,000,000
Pretax Income TTM
$12,586,000,000
Interest Exp TTM
$1,746,000,000
Analysts
10
Yahoo Snapshot (yfinance, live)
Total Revenue
$61,366,001,664
EBITDA
$19,904,000,000
Free Cash Flow
$4,905,375,232
Enterprise Value
$275,880,673,280
Total Cash
$4,968,000,000
Total Debt
$32,349,999,104
Shares Out
1,550,895,914
Trailing EPS
$6.68
Book Value
$32.43
ROE
22.0%
ROA
8.0%
Div Yield
2.00%
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 58,739,000,000 | 13,327,000,000 | 10,225,000,000 | 114,074,000,000 | 65,355,000,000 | 48,667,000,000 | 14,575,000,000 |
| Dec 2024 | 54,073,000,000 | 10,251,000,000 | 7,035,000,000 | 104,035,000,000 | 63,164,000,000 | 40,786,000,000 | 11,861,000,000 |
| Dec 2023 | 45,811,000,000 | 8,722,000,000 | 5,955,000,000 | 101,119,000,000 | 61,953,000,000 | 39,143,000,000 | 10,345,000,000 |
| Dec 2022 | 44,351,000,000 | 4,512,000,000 | 3,288,000,000 | 96,483,000,000 | 59,425,000,000 | 37,037,000,000 | 9,808,000,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$11.36
Max Pain — expiry 2026-10-16
max pain strike: $165.00 · spot: $167.02 · call oi: 29,890 · put oi: 12,103
Expected Move to 2026-10-16:
±$8.35
(5.00%) —
implied range
$158.67 –
$175.37
· ATM straddle on $165.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| NVS | NOVARTIS AG | $276.48B | $145.46 | — |
| MRK | Merck & Co., Inc. | $367.07B | $148.78 | — |
| ABT | ABBOTT LABORATORIES | $175.27B | $101.29 | — |
| PFE | PFIZER INC | $163.41B | $28.67 | — |
| ABBV | AbbVie Inc. | $467.12B | $264.34 | — |
News headlines (Yahoo Finance, 1h cache)
Is AstraZeneca's Oncology Portfolio Positioned for Continued Growth?
2026-09-28 13:02 · Yahoo
AstraZeneca (AZN): Can Precision Medicine Offset a Narrower Breast Cancer Market?
2026-09-24 22:20 · Yahoo
AstraZeneca's Trixeo Secures Approval for Asthma in the EU
2026-09-23 15:00 · Yahoo
European big pharma unites amid ‘ringing alarm bells’ of continent’s dominance
2026-09-23 14:52 · Yahoo
Ozempic-maker Novo open to upgrading US listing
2026-09-23 04:00 · Yahoo
AstraZeneca and GSK warn Europe’s drug industry is ‘at risk’
2026-09-22 19:26 · Yahoo
Sanofi's New Drugs Poised to Drive Growth Beyond Dupixent
2026-09-25 13:30 · Yahoo
IRLAB Appoints Janne Backman as New Chairman of the Board
2026-09-24 15:45 · Yahoo
What Bavarian Nordic’s next CEO is up against
2026-09-28 12:50 · Yahoo
Sector Update: Healthcare Stocks Edge Higher in Afternoon Trading
2026-09-25 17:57 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.